Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Rituximab 9Cyclophosphamide 8fludarabine 5dacetuzumab 5blinatumomab 5Brentuximab Vedotin 4Bendamustine Hydrochloride 4ibrutinib 3fludarabine phosphate 3Vincristine 3Prednisone 3Melphalan 3Etoposide 3Doxorubicin 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Ifosfamide 2Everolimus 2Cytarabine 2Carboplatin 2Busulfan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Diseases × amonafide × Clear all
NCT00715637 2010-10-13

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Antisoma Research

Phase 3 Unknown
420 enrolled
Other hematologic neoplasm

Leukemia, Lymphatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡